Journal
JOURNAL OF CLINICAL MEDICINE
Volume 11, Issue 11, Pages -Publisher
MDPI
DOI: 10.3390/jcm11113099
Keywords
COVID-19; heparin; low molecular weight heparin; coagulopathy; thromboprophylaxis
Categories
Ask authors/readers for more resources
COVID-19 is associated with an increased risk of VTE and coagulopathy, with endothelial damage being a crucial mechanism. Heparin has multiple biological actions in the treatment of COVID-19.
Coronavirus disease 2019 (COVID-19) is associated with an increased risk of venous thromboembolism (VTE) and coagulopathy, especially in critically ill patients. Endothelial damage induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a crucial pathogenetic mechanism for the development of complications in an acute phase of the illness and for several postdischarge sequalae. Heparin has been shown to have a positive impact on COVID-19 due to its anticoagulant function. Moreover, several other biological actions of heparin were postulated: a potential anti-inflammatory and antiviral effect through the main protease (M-pro) and heparansulfate (HS) binding and a protection from the damage of vascular endothelial cells. In this paper, we reviewed available evidence on heparin treatment in COVID-19 acute illness and chronic sequalae, focusing on the difference between prophylactic and therapeutic dosage.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available